NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer

PD-1/PD-L1-blockade immunotherapies have limited efficacy in the treatment of muscle-invasive bladder cancer (MIBC) and metastatic urothelial carcinoma. Here, we show that KLRC1 (NKG2A) expression associates with improved survival and responsiveness to PD-L1 blockade immunotherapy in CD8Ahigh bladder tumors. The loss of antigen presentation is a common mechanism for tumor escape in bladder cancer. NKG2A+ CD8 T cells are able to circumvent HLA-ABC loss through TCR-independent cytotoxicity, which is partly mediated by DNAM-1. In bladder tumors, NKG2A is acquired on a subset of PD-1+ CD8 T cells, alongside stronger tissue-residency memory features, TCR-independent cytotoxicity and evidence of recent proliferation. HLA-E is low but variably expressed on bladder tumors. When expressed, NKG2A+ CD8 T cell anti-tumor responses to HLA-ABC-deficient tumors are inhibited and partly restored upon NKG2A blockade. Overall, our study identifies an alternative path for CD8 T cell exhaustion, that is mediated by NKG2A upregulation and TCR-independent cytotoxicity.

[1]  J. Witjes,et al.  Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. , 2021, The New England journal of medicine.

[2]  Thomas D. Wu,et al.  Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade , 2021, Journal for ImmunoTherapy of Cancer.

[3]  Y. Bang,et al.  Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. , 2021, JAMA oncology.

[4]  Jinyan Huang,et al.  CytoTree: an R/Bioconductor package for analysis and visualization of flow and mass cytometry data , 2021, BMC Bioinformatics.

[5]  H. Wanibuchi,et al.  Tertiary lymphoid structures show infiltration of effective tumor‐resident T cells in gastric cancer , 2021, Cancer science.

[6]  Wun-Jae Kim,et al.  TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. , 2020, Cancer letters.

[7]  R. Hannan,et al.  Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. , 2020, European urology oncology.

[8]  J. Goedert,et al.  HLA tapasin independence: broader peptide repertoire and HIV control , 2020, Proceedings of the National Academy of Sciences.

[9]  E. Schadt,et al.  Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing , 2020, Clinical Cancer Research.

[10]  F. Gao,et al.  Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. , 2020, Cancer discovery.

[11]  W. Oh,et al.  Treatment of muscle‐invasive and advanced bladder cancer in 2020 , 2020, CA: a cancer journal for clinicians.

[12]  R. Motzer,et al.  Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. , 2020, Cancer.

[13]  Chun Jimmie Ye,et al.  Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer , 2020, Cell.

[14]  M. Galsky,et al.  Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.

[15]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[16]  J. Wilmott,et al.  Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition , 2020, Nature Communications.

[17]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[18]  G. Freeman,et al.  Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. , 2019, Immunity.

[19]  S. H. van der Burg,et al.  Monalizumab: inhibiting the novel immune checkpoint NKG2A , 2019, Journal of Immunotherapy for Cancer.

[20]  M. Shipp,et al.  Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087. , 2019, Blood.

[21]  David C. Smith,et al.  Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab , 2019, JAMA oncology.

[22]  N. Sebire,et al.  Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition , 2019, Nature Communications.

[23]  P. Hogan,et al.  TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion , 2019, Proceedings of the National Academy of Sciences.

[24]  E. V. Van Allen,et al.  Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[25]  E. Wherry,et al.  CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. , 2019, Annual review of immunology.

[26]  Jeffrey S. Miller,et al.  Setting traps for NKG2A gives NK cell immunotherapy a fighting chance. , 2019, The Journal of clinical investigation.

[27]  O. Lantz,et al.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells , 2018, Cell.

[28]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[29]  T. Schumacher,et al.  T Cell Dysfunction in Cancer. , 2018, Cancer cell.

[30]  Benjamin J. Raphael,et al.  Abstract PR03: Genetic mechanisms of immune evasion in colorectal cancer , 2018, Systems Immuno-Oncology.

[31]  A. Kamphorst,et al.  CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. , 2018, Annual review of medicine.

[32]  J. Goedert,et al.  Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells , 2018, Science.

[33]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[34]  J. Becker,et al.  Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma , 2017, Scientific Reports.

[35]  Ronald D. Vale,et al.  T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition , 2016, Science.

[36]  Koichi Araki,et al.  Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent , 2016, Science.

[37]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[38]  D. Pardoll,et al.  TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. , 2016, Cancer discovery.

[39]  V. Boussiotis.  Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. , 2016, The New England journal of medicine.

[40]  P. Parham,et al.  Class I HLA haplotypes form two schools that educate NK cells in different ways , 2016, Science Immunology.

[41]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[42]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[43]  W. Shi,et al.  Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes , 2016, Science.

[44]  F. Garrido,et al.  The urgent need to recover MHC class I in cancers for effective immunotherapy , 2016, Current opinion in immunology.

[45]  Tianxin Lin,et al.  CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder. , 2015, The Journal of urology.

[46]  F. Mami-Chouaib,et al.  CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. , 2013, Cancer research.

[47]  F. Mami-Chouaib,et al.  Microenvironment and Immunology CD 103 or LFA-1 Engagement at the Immune Synapse between Cytotoxic T Cells and Tumor Cells Promotes Maturation and Regulates T-cell Effector Functions , 2013 .

[48]  Takashi Saito,et al.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 , 2012, The Journal of experimental medicine.

[49]  M. Huber,et al.  A Th17‐like developmental process leads to CD8+ Tc17 cells with reduced cytotoxic activity , 2009, European journal of immunology.

[50]  T. Strutt,et al.  Tc17, a Unique Subset of CD8 T Cells That Can Protect against Lethal Influenza Challenge1 , 2009, The Journal of Immunology.

[51]  A. Gunturi,et al.  The role of TCR stimulation and TGF‐β in controlling the expression of CD94/NKG2A receptors on CD8 T cells , 2005, European journal of immunology.

[52]  Adanma Ndubuizu,et al.  The ALX Src Homology 2 Domain Is Both Necessary and Sufficient to Inhibit T Cell receptor/CD28-mediated Up-regulation of RE/AP* , 2004, Journal of Biological Chemistry.

[53]  T. Wheeler,et al.  Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder , 2001, Cancer.

[54]  D. Speiser,et al.  In Vivo Expression of Natural Killer Cell Inhibitory Receptors by Human Melanoma–Specific Cytolytic T Lymphocytes , 1999, The Journal of experimental medicine.

[55]  L. Sobin,et al.  Histological Typing of Urinary Bladder Tumours , 1999, International Histological Classification of Tumours.

[56]  R. Bellomo,et al.  Transforming growth factor‐β‐induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes , 1999, European journal of immunology.

[57]  J. Coligan,et al.  Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell-associated CD94/NKG2 receptors. , 1999, Immunity.

[58]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[59]  Andrew G. Brooks,et al.  NKG2A Complexed with CD94 Defines a Novel Inhibitory Natural Killer Cell Receptor , 1997, The Journal of experimental medicine.

[60]  M. Carretero,et al.  The CD94 and NKG2‐A C‐type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules , 1997, European journal of immunology.

[61]  T. Crook,et al.  Viral infection and cancer , 1995, The Lancet.

[62]  M. Balboa,et al.  A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-gamma/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody. , 1990, Journal of immunology.

[63]  J. Joubert.  Carcinoma of the bladder. , 1955, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.